Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. PT Jayamas Medica Industri Tbk's selling, general, & admin. expense for the
three
months ended in Jun. 2026 was Rp49,144 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2026 was Rp169,541 Mil.
PT Jayamas Medica Industri Tbk (ISX:OMED) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
PT Jayamas Medica Industri Tbk Selling, General, & Admin. Expense Related Terms
PT Jayamas Medica Industri Tbk Selling, General, & Admin. Expense Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Jayamas Medica Industri Tbk Selling, General, & Admin. Expense Chart
ISX:OMED vs ISRG, BDX, MDLN: Selling, General, & Admin. Expense Comparison
For the Medical Instruments & Supplies subindustry, PT Jayamas Medica Industri Tbk's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Jayamas Medica Industri Tbk Selling, General, & Admin. Expense vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PT Jayamas Medica Industri Tbk's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where PT Jayamas Medica Industri Tbk's Selling, General, & Admin. Expense falls into.
PT Jayamas Medica Industri Tbk Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp169,541 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of Rp169,541 Mil mean?
PT Jayamas Medica Industri Tbk (ISX:OMED) has a Selling, General, & Admin. Expense of Rp169,541 Mil as of Jun. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on PT Jayamas Medica Industri Tbk and its competitors.
Is PT Jayamas Medica Industri Tbk's Selling, General, & Admin. Expense too high?
PT Jayamas Medica Industri Tbk's current Selling, General, & Admin. Expense is Rp169,541 Mil. Overall, PT Jayamas Medica Industri Tbk has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PT Jayamas Medica Industri Tbk's Selling, General, & Admin. Expense compare to ISRG and BDX?
PT Jayamas Medica Industri Tbk's Selling, General, & Admin. Expense of Rp169,541 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Medical Devices & Instruments company?
A good Selling, General, & Admin. Expense depends on the Medical Devices & Instruments industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on PT Jayamas Medica Industri Tbk and its competitors. PT Jayamas Medica Industri Tbk's current Selling, General, & Admin. Expense is Rp169,541 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Jayamas Medica Industri Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk (ISX:OMED) is currently considered Fairly Valued. The stock's GF Value™ is Rp239.64, compared to a current price of Rp232.00 — trading 3.2% below its estimated fair value. The current Selling, General, & Admin. Expense is Rp169,541 Mil. PT Jayamas Medica Industri Tbk's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For PT Jayamas Medica Industri Tbk (ISX:OMED), the current Selling, General, & Admin. Expense is Rp169,541 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Jayamas Medica Industri Tbk (ISX:OMED) Overvalued in 2026?
Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk stock appears to be undervalued.
The current stock price of Rp232.00 is trading 3.2% below its estimated GF Value™ of Rp239.64.
GuruFocus considers PT Jayamas Medica Industri Tbk to be Fairly Valued.
Key valuation signals for ISX:OMED:
Selling, General, & Admin. Expense: Rp169,541 Mil
GF Value™: Rp239.64 vs. price of Rp232.00 (3.2% below fair value)
No single metric tells the full story. See the ISX:OMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Jayamas Medica Industri Tbk is engaged in the business of manufacturing, wholesale and retail trade of medical devices. Its offerings include Disposable and Expendable Medical Supplies, Wound Care, Diagnostics and Equipment, Antiseptics and Dialysis, Biotechnology and Laboratory, Ambulatory and Rehabilitation Care The company has three segments: i) Manufacturing: This division is involved in the manufacturing of medical supplies and equipment, ii) Distribution: This division is involved with the large scale distribution of medical supplies and equipment at strategic locations, iii) Retail: This division is involved with the retail of medical supplies and equipment through Medicom stores and online platforms. The majority of the company's revenue is derived from the Distribution segment.
90GF Score
Get the complete analysis for ISX:OMED
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:OMED has been successfully added to your 
